Answers are grounded in this paper and cite their sources.
Adaptive resistance to HER2-targeted tyrosine kinase inhibitors (TKIs) such as lapatinib and tucatinib limits durable responses in HER2-positive breast cancer. While tumor-intrinsic resistance mechanisms are well studied, the role of extratumoral cues in therapy adaptation remains unclear. Here we demonstrate that extratumoral insulin-like growth factor-1 (IGF-1) is a critical mediator of adaptive TKI resistance. TKI treatment induces oxidative stress, marked by elevated mitochondrial reactive oxygen species (ROS), lipid peroxidation, and DNA damage. Single-cell analysis and fibroblast co-culture experiments identify stromal fibroblasts as the primary source of this IGF-1. This stromal IGF-1 activates a PI3K/FOXO/NRF2 axis in TKI-stressed tumor cells that suppresses KEAP1, stabilizes NRF2, and restores redox homeostasis, allowing cancer cells to persist. Inhibiting IGF-1R or PI3K blocks NRF2 activation and restores TKI sensitivity, making this a targetable resistance mechanism. IGF-1 signaling also remodels the tumor secretome and drives macrophage polarization toward an immunosuppressive M2 phenotype, further supporting tumor survival. Consistent with this, residual tumors from HER2-TKI-treated patients showed upregulated IGF-1R signaling and a partial antioxidant gene signature. IGF-1/PI3K/NRF2 pathway activity correlated with M2 macrophage infiltration across TCGA breast cancer cohorts. Together, these findings identify a pharmacologically actionable, microenvironment-driven redox adaptation axis that links tumor cell survival to immune modulation and suggest that co-targeting IGF-1/PI3K/NRF2 signaling could improve the efficacy of HER2-targeted therapy. Durable responses to targeted therapy may depend not only on disrupting tumor-intrinsic signaling but also on the stromal and immune microenvironment tumors co-opt to survive treatment.
No takes yet. Share an insight, caveat, or question.
Dutta et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: